Research Article Details
| Article ID: | A13177 |
| PMID: | 30099414 |
| Source: | Wiad Lek |
| Title: | Pathogenesis of insulin resistance in pregnant women with obesity. |
| Abstract: | OBJECTIVE: Introduction: Obesity is one of the most important medical and social problems in many countries of the world, as it is associated with the development of the most common non-communicable diseases: cardiovascular, type II diabetes mellitus, motor disorders, non-alcoholic fatty liver disease (NHAHP) and others. The aim of this paper is to analyze the pathogenetic mechanisms of insulin resistance development in pregnant women with varying obesity degrees in early and late gestation periods. PATIENTS AND METHODS: Materials and methods: 459 pregnant women were examined at the Poltava City Clinical Maternity Hospital in the early (9-13 weeks) and late gestation periods (34-38 weeks). Metabolic disorders in pregnant women were studied by carbohydrate and lipid metabolism indices. RESULTS: Results: Due to increased insulin resistance and reduced glucose absorption by tissues of pregnant women with obesity, there are prerequisites for the development of energy insufficiency. Obese women pregnancy runs on the background of hypertriglyceridemia and type IV hyperlipoproteinemia. The general pathogenic consequence of the insulin resistance progression during pregnancy in obese women is an energy deficiency increase, which causes a threatening obstetric and perinatal complications frequency increase. CONCLUSION: Conclusions: The progression of insulin resistance during pregnancy of women with varying degrees of obesity is the pathogenetic basis of energy insufficiency and the reduction of adaptive mechanisms of pregnant women with obesity, as evidenced by the increase in obstetric and perinatal complications frequency. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs | |
|---|---|---|---|---|---|
| S01 | Improve insulin resistance | insulin sensitizer; insulin resistance; glucose tolerance | Biguanide: increases 5-AMP activated protein kinase signaling; SGLT-2 inhibitor; Thiazalidinedione: selective PPAR-γ agonists; GLP-1 agonist | Metformin; Empagliflozin; Canagliflozin; Rosiglitazone; Pioglitazone; Liraglutide | Details |
| S02 | Enhance lipid metabolism | triglyceride-lowering; lipid tolerance; lipid metabolism | 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) inhibitor; Decreases intestinal cholesterol absorption; FXR agonist; ACC inhibitor; FAS inhibitor; DGAT2 inhibitor; SCD-1 inhibitor | Atorvastatin; Ezetimibe; Obeticholic Acid; GS-9674; GS-0976; TVB-2640; IONIS-DGAT2rx; Aramchol; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I13 | 3146 | Lipid metabolism disorder | An inherited metabolic disorder that involves the creation and degradation of lipids. http://en.wikipedia.org/wiki/Lipid_metabolism | disease of metabolism/ inherited metabolic disorder | Details |
| I05 | 9352 | Type 2 diabetes mellitus | A diabetes that is characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both. A diabetes mellitus that is characterized by high blood sugar, insulin resistance, and relative lack of insulin. http://en.wikipedia.org/wiki/Diabetes, http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 | disease of metabolism/inherited metabolic disorder/ carbohydrate metabolic disorder/glucose metabolism disease/diabetes/ diabetes mellitus | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |